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Obesity increases the risk of colon cancer as well as the expression of many cancer 
markers, ostensibly due to the interaction between insulin resistance and adipocyte production 
of hormones, mitogens and cytokines which collaborate to enhance proliferation signaling and 
impair the DNA damage response. Cdc7 and PCNA are both proteins involved in the DNA 
damage response as well as DNA replication. Both have also been shown to be upregulated in 
human tumours. To assess Cdc7 and PCNA roles during the DNA damage response in obese 
and lean animals, we administered azoxymethane (AOM), a colon-specific carcinogen, to 
obese and lean rats. Cdc7 and PCNA levels in colonic mucosal protein extracts from obese 
Zucker rats were compared with those from their lean counterparts. Significant differences 
were seen between lean and obese animals 3 hours post-AOM (lean Cdc7 levels > obese Cdc7 
levels) and 24 hours post-AOM (lean PCNA levels > obese PCNA levels). This result 
suggests an impaired checkpoint response in obese animals relative to lean animals and 
supports a previously reported early role for Cdc7 in the checkpoint signaling cascade relative 
to a later role of PCNA in DNA damage repair. At the time tumours appeared (32 weeks post-
AOM), colonic mucosal Cdc7 levels of obese rats exce ded that of their lean counterparts, 
suggesting that the obese metabolic environment causes pregulation of Cdc7 in obese rat 
epithelia. Cdc7 and PCNA levels were then compared between tumours and mucosa in obese 
and Sprague Dawley rats. Tumour Cdc7 levels were upg lated relative to mucosal levels in 
more samples than tumour PCNA levels, suggesting Cdc7 may be a more sensitive tumour 
marker.  No significant differences in Cdc7 levels were seen between obese tumours and 
mucosa, likely due to elevation of obese mucosal Cdc7 levels. However, Sprague Dawley 
(non-obese) rats showed significantly higher Cdc7 and PCNA levels in tumours than mucosa, 
consistent with previous studies in human tissues. These results suggest that Cdc7 may be a 
more sensitive tumour marker than PCNA, but that its utility as a biomarker of colon cancer is 





Thank you to my supervisor, Dr. Ranjana Bird, for valuable 
perspective and expert advice. It has truly been an honour. 
Thank you, Bernie D., for putting an amazing amount of time and 
effort into your ‘adopted’ student. I appreciate every minute you have spent 
collaborating to make this project the best it can be. 
Thank you, Mungo, for laughter and perspective on the big picture of 
which grad studies is only a part. How does one distinguish between “honest 
and forthright” and “blunt and grumpy?” ;) 
Thank you, Vivian, an exceptionally energetic working mom who 
inspired me greatly when I needed balance the most. 
Thank you, Dragana, Christine, Niels, Norm, & Cheryl, for aiding and 
abetting my love of teaching; Bernie G. & Brian D. for extending wings I 
could shelter under; and Michael P., for friendship and insight, scientific and 
otherwise. :) 
Many thanks to previous Bird lab members, especially...  
Nita – I am not good at everything. That’s you. :) 
...and Nafiseh – You made coming to school delightful. I am so-o-o 
glad you were the second-last one to leave!  
Thanks to the members of the Duncker lab, for your friendship, 
kindness and willingness to help out your neophyte ‘adopted’ lab-mate. 
And finally, thank you to Peter, Candace, Kyle, Alex & Julie –  






To my gorgeous, wonderful family: Peter, 
Candace, Kyle, Alexander & Julie, without 
whose love and support this document, and the 
rest of my life, would be blank pages. 
 
To Dad...wish you could have been here to see 
the wedding, the little babies, and my 
graduation... 
 
To Mom, for her shining example. 
xi 
 
Table of Contents 
List of figures ..........................................................................................................................xiii 
List of abbreviations ............................................................................................................... xv 
Chapter 1. Introduction ....................................................................................................... 1 
1.1 Overview ............................................................................................................... 1 
1.2 Colon cancer......................................................................................................... 2 
1.2.1 Tumourigenesis in the mammalian colon ........................................................ 2 
1.2.2 Early detection of colon cancer .................................................................... 6 
1.3 Protein markers of colon cancer .......................................................................... 9 
1.4 Nucleic acid markers of colon cancer ........................................................................ 9 
1.5 DNA replication and the cell cycle ..................................................................... 12 
1.6 DNA damage detection and repair .................................................................... 17 
1.7 Cdc7 and PCNA as cancer biomarkers ............................................................ 21 
1.8 Predisposition of overweight and obese animals to col n cancer ................................. 22 
1.8.1.a Animal models of obesity ............................................................................. 23 
1.9 Objectives and hypotheses ....................................................................................... 25 
Chapter 2. Materials and Methods ................................................................................... 27 
2.1 Rat strains ........................................................................................................... 27 
2.1.1 Zucker ......................................................................................................... 27 
2.1.2 Sprague Dawley ......................................................................................... 29 
2.2 Tissue collection....................................................................................................... 31 
2.3 Tissue homogenization and extraction of soluble proteins ........................................... 31 
2.4 Western Blot............................................................................................................. 32 
xii 
 
2.5 Densitometry and statistical analysis ................................................................ 34 
Chapter 3. Results .............................................................................................................. 35 
3.1 Animal weights ................................................................................................... 35 
3.2 Study 1: Early events in colon carcinogenesis in Zucker obese and lean rats .............. 37 
3.2.1 Cdc7 levels are increased in lean colonic mucosa relativ  to obese by 3h post-
AOM 37 
3.2.2 PCNA levels are not significantly higher in lean colonic mucosa relative to obese 
until after 9 hours post-AOM .................................................................................. 47 
3.3 Study 2: Late events in colon carcinogenesis in Zucker obese and lean rats ................ 48 
3.3.1 Cdc7, but not PCNA, abundance is significantly higher in obese colon mucosa 
relative to lean late in carcinogenesis.................................................................... 48 
3.3.2 PCNA, but not Cdc7, levels are significantly higher in obese tumours relative to 
adjacent mucosa .................................................................................................... 52 
3.4 Study 3: Late events in colon carcinogenesis in the Sprague Dawley rat model .......... 59 
3.4.1 Cdc7 and PCNA levels are increased in AOM-induced colonic tumours in 
Sprague Dawley rats .................................................................................................... 59 
Chapter 4. Discussion ......................................................................................................... 63 
4.1 DNA damage response appears more robust in lean than obese .................................. 64 
4.2 Temporal order of Cdc7 and PCNA upregulation is consistent with respective roles in 
DNA damage signaling and fork restart........................................................................... 65 
4.3 Cdc7 protein upregulation in tumours does not extend o the obese rat model ............ 67 
4.4 Cdc7 and PCNA protein upregulation in human tumours extends to a Sprague Dawley 
rat model........................................................................................................................... 70 
4.5 Conclusions and future directions ............................................................................ 71 
Appendix - Supplementary Figures ....................................................................................... 75 




List of figures 
 
Figure 1. Photograph (A) and cartoon rendering (B) of a colonic crypt immunostained to 
show proliferating cells. . ........................................................................................................... 4 
Figure 2. Colonic crypt morphology is altered in response to DNA damage. ......................... 5 
Figure 3. Somatic mutations cause the progression of colon cancer. DNA damage converts 
normal colonic crypts to hyperplastic ACF. ... .......................................................................... 8 
Figure 4. Initiation of DNA replication. ................................................................................. 14 
Figure 5. Phases of the cell cycle. ... ....................................................................................... 16 
Figure 6. Cdc7 is involved in claspin-mediated ATR signaling. ..... ...................................... 20 
Figure 7. Experimental design for Zucker studies (Study 1 and Study 2). ............................. 28 
Figure 8. Experimental design for Sprague Dawley study (Study 3)...................................... 30 
Figure 9. Obese rats are significantly heavier than age-matched lean rats at both termination 
timepoints. ............................................................................................................................... 36 
Figure 10. No significant differences were seen in Cdc7 or PCNA expression between the 
colonic mucosa of obese and lean uninjected Zucker rats. ...................................................... 38 
Figure 11. Higher Cdc7 levels in the colonic mucosa of lean relative to obese rat colonic 
mucosa 3h post-carcinogen challenge is consistent with checkpoint-associated upregulation of 
Cdc7 favoured in lean rats........................................................................................................ 40 
Figure 12. No significant difference in Cdc7 or PCNA expression was seen in the colonic 
mucosa of lean relative to obese rats 9h post-carcinogen challenge. .. .................................... 42 
Figure 13. Higher PCNA levels in lean relative to obese rat colonic mucosa 24 hours after 
DNA damage is consistent with PCNA role in DNA damage repair favoured in lean rats. .... 44 
Figure 14. Cdc7 levels are higher in obese normal-appearing colonic mucosa vs. lean once 
tumours have appeared. .... ....................................................................................................... 50 
Figure 15. Obese colonic mucosa expresses similar levels of Cdc7, but not PCNA, to obese 
colonic tumours. . ..................................................................................................................... 54 
Figure 16. Summary of obese vs. lean rat colonic protein expression during colon 
carcinogenesis: Cdc7 levels correlate with degree of hyperproliferation, whereas increased 
PCNA levels appear to indicate presence of neoplasia. ........................................................... 56 
xiv 
 
Figure 17. Cdc7 and PCNA levels are significantly increased in tumours vs. normal-
appearing colon mucosa in Sprague Dawley rats........ ........................................................... 60 
Figure 18. Role of Cdc7 and PCNA in DNA damage response and obese cancer risk. .. ...... 72 
Appendix Figures 
Figure A 1. No significant differences in Cdc7 or PCNA level were seen between timepoints 
during early events in obese Zucker colonic mucosa............................................................... 76 
Figure A 2. No significant differences in Cdc7 or PCNA level were seen between timepoints 
during early events in lean Zucker colonic mucosa. ................................................................ 78 
Figure A 3. The single lean tumour appeared to express more PCNA but not Cdc7 than lean 
mucosa. .................................................................................................................................... 80 
Figure A 4. The single lean tumour falls within the distribution of obese Cdc7 and PCNA 
expression. ................................................................................................................................ 81 
Figure A 5. MCM2 antibody did not have sufficient affinity for Sprague Dawley protein. .... 82 




List of abbreviations 
 
ACF aberrant crypt foci 
And-1 acidic nucleoplasmic DNA-binding protein 1, also known as WDHD1 
AOM azoxymethane 
ASK associated with S-phase kinase (mammalian homologue of Dbf4) 
ATM ataxia telangiectasia mutated 
ATP adenosine triphosphate 
ATR ATM- and Rad 3-related 
Cdc7 cell division cycle protein 7 (S-phase kinase) 
Cdc45 cell division cycle protein 45 (accessory factor for MCM) 
Cdk cyclin-dependent kinase 
CEA carcinoembryonic antigen 
Chk1 checkpoint kinase 1 
Chk2 checkpoint kinase 2 
CRC colorectal cancer 
DNA deoxyribonucleic acid 
DSB double-stranded break 
FOBT faecal occult blood test 
GINS go ichi nii san, Japanese words for Sld5-Psf1-Psf2-Psf3, its subunits 
Ki-67 Kiel-67 (named after city in which antibody was first made) 
MAM methylazoxymethanol 
MCM minichromosome maintenance complex 
xvi 
 
Mcm1-10 minichromosome maintenance proteins 1-10 
OL quotient of means, obese/lean 
ORC origin recognition complex 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PIKK phosphatidylinositol 3-kinase-related kinase 
Psf1-3 partner of Sld5, 1-3 
Rb retinoblastoma protein 
RFC replication factor C 
RNA ribonucleic acid 
Sld5 synthetically lethal with Dpb11-5 
SSB single-stranded break 














Chapter 1.  Introduction 
1.1 Overview 
 In Canada, cancer of the colon is the second leading cause of cancer death in males 
and the third leading cause of cancer death in females, ccounting for approximately 12 
percent of the total cancer deaths in both genders (Canadian Cancer Society's Steering 
Committee, 2009). The importance of early detection in optimizing prognosis and minimizing 
the cost of this disease has led to the discovery of a plethora of tumour markers. Protein 
tumour markers currently include replication factors such as proliferating cell nuclear antigen 
(PCNA), cyclin D1, cyclin E, Mcm2 and Cdc7 (Gould Rothberg et al., 2009; Kwee & Kwee, 
2008; Semple & Duncker, 2004; Srivastava et al., 2001; Velmurugan et al., 2008). Variability 
amongst cancers coupled with the inconsistency of individual markers in accurately detecting 
cancer fuels the search for new candidates. Since cancer cells utilize a dysregulated DNA 
damage response to survive their increased mutation rate, replication factors that are also 
involved in DNA damage response may have increased lik lihood of overexpression in cancer 
cells. Recent studies have revealed a novel, active role of the DNA replication kinase Cdc7 in 
checkpoint signaling (Kim et al., 2008; Tenca et al., 2007). Similarly, the replication fork 
component PCNA has known roles in DNA damage repair (reviewed in Moldovan et al., 
2007). In this work, levels of Cdc7 and PCNA protein were assessed to determine if they 
mirrored their sequential involvement in DNA damage response immediately following 
carcinogen challenge in a rat model of colon carcinogenesis.  Further, previous studies 
demonstrating impaired DNA damage 
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 response and enhanced cellular proliferation in obese animals (Jaiswal et al., 2000; Mena et 
al., 2009; Zeng et al., 2008) suggested that obese pathophysiology could affect the robustness 
of the DNA damage response and the ability of both Cdc7 and PCNA to discriminate between 
tumour and non-tumour tissues. The performance of Cdc7 and PCNA as tumour markers in 
obese animals was assessed using obese, lean and Spr gue-Dawley rat models of AOM-
induced colon cancer. 
1.2 Colon cancer 
1.2.1 Tumourigenesis in the mammalian colon 
The mammalian colon consists of three layers: the mucosa, which lines the interior 
(lumen) of the colon and contains primarily epithelial cells; the submucosa, which lies radially 
outside of the mucosa and is comprised of connectiv tissue; and the muscularis, the outermost 
muscular lining of the colon responsible for advancement of the feces. CRC is characterized 
by uncontrolled proliferation of colonic or rectal epithelial cells (Shibata, 2006; Vogelstein & 
Kinzler, 2004).  Normal colonic mucosal epithelial ce ls begin as epithelial stem cells at the 
base of crypts in a region known as a niche (Shibata, 2006) (Figure 1). Mesenchymal cells 
beneath the basement membrane at the base of the crypt signal stem cells to remain 
undifferentiated. Stem cell progeny which leave the niche differentiate, migrate up the sides of 
the crypt towards the lumen, and eventually die and are sloughed off in the feces (Yen & 
Wright, 2006). DNA damage causes hyperproliferative changes in crypt architecture resulting 
in aberrant crypts (Bird & Good, 2000).  Clusters of aberrant crypts known as aberrant crypt 
foci (ACF) (Figure 2) are identified by their abnormal morphology relative to nearby crypts: 
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they have enlarged, sometimes elongated luminal openings, thicker epithelial lining, and a 
well-defined pericryptal zone (Bird, 1987; McLellan et al., 1991a). ACF arise in the colon 
following carcinogen exposure in a dose- and time-dependent manner (McLellan et al., 





Figure 1. Photograph (A) and cartoon rendering (B) of a colonic crypt 
immunostained to show proliferating cells. Stem cells proliferate at the crypt base 
exclusively in the niche (round cells boxed in green in (B)). Cells which leave the niche 
divide a finite number of times as they migrate up the crypt wall toward the luminal end of 
the crypt. Eventually, they cease replicating, die,and are sloughed off. Cartoon adapted 
from Shibata, 2008, Fig. 1. 
A. B. 








luminal end of crypt 
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Figure 2. Colonic crypt morphology is altered in response to DNA damage.   
Left panel:  Methylene-blue stained mucosa viewed from the luminal side 
contains crypts of uniform size and shape.  Right panel: The same stain and view 
of an aberrant crypt focus demonstrates the differences in architecture of the 
crypts brought about by carcinogen challenge.  Note that the focus protrudes into 
the lumen, and the luminal opening of each crypt of the focus is irregularly 
shaped, particularly in comparison to the normal crypts which can be seen in the 
background. Magnification: 400x. 
carcinogen 
challenge 




  Most ACF either cease to progress or eventually revert to normal tissue (Bird, 1995; 
Bird & Good, 2000). ACF can be classed according to the number of aberrant crypts involved 
in a particular focus; this feature of ACF is known as crypt multiplicity. Dysplastic ACF and 
ACF of high crypt multiplicity are thought to be particularly likely to progress to CRC (Gupta 
et al., 2007; Magnuson et al., 1993; Takayama et al., 2005). ACF that progress to CRC first 
become adenomatous polyps (benign tumours) which can be distinguished from carcinoma by 
growth confinement to the mucosal layers. Dysplastic cells in polyps have acquired additional 
mutations which confer a selective advantage which causes them to proliferate more 
effectively than other cells in the same crypt (Vogelstein & Kinzler, 2004), a phenomenon 
known as clonal selection. Additional mutations in polyp cells can lead to the selection of cell 
clones which are not restricted to the mucosal layers, known as neoplastic cells, resulting in 
carcinoma (malignant tumour) (Figure 3). Only a fraction of polyps have malignant potential 
to invade the muscular layers beneath the mucosa (Srivastava et al., 2001).  
Colon carcinoma can be due in part to germline mutations which confer a highly 
increased risk for cancer development (hereditary CRC) or can arise solely due to somatic 
mutations (sporadic CRC) (Jass, 2002). Over 70% of CRCs are sporadic in nature (Benson, 
2007), making models of sporadic CRC such as AOM-induced colon cancer a relevant tool in 
the search for useful cancer biomarkers. 
1.2.2 Early detection of colon cancer 
Early diagnosis of colon cancer improves the 5-year survival rate by 25-80% 
(Turnbull et al., 1997). Current detection and screening methods include colonoscopy, digital 
(with the fingers) rectal exam, barium enema, and the faecal occult blood test (FOBT)  
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(Beckman-Coulter).  Since non-invasive methods are desirable for routine screening due to 
convenience, cost, comfort and reduced health risk to the patient (Ransohoff, 2002), the 
FOBT is the screening method of choice, with recent advances indicating higher sensitivity of 
immunochemical detection of hemoglobin over tests based on the chemical guaiac (Gimeno-
Garcia et al., 2009).  The presence of hemoglobin in the stool is, however, not perfectly 
correlated with cancer presence, as other diseases c n also lead to colorectal bleeding. Also, 
polyps and even some carcinomas bleed intermittently a d are therefore difficult to detect by 
this method alone (Turnbull et al., 1997). New detection targets are therefore needed to 
increase sensitivity of fecal testing.  
Detection of molecules preferentially expressed in ca cer cells relies on the favoured 
presence of polyp and cancer cells in stool. Polyp cells and carcinoma cells are non-apoptotic 
and are sloughed off at a greater rate than normal colonic epithelial cells (Loganayagam, 
2008). This feature has been exploited to detect mutated DNA in feces of cancer patients; 
however, cost prohibits the routine use of DNA screening (Huerta, 2008). Since 
immunochemical methods have been successfully used to detect hemoglobin in feces 
(Gimeno-Garcia et al., 2009), protein biomarkers of CRC could become supplementary 
immunochemical targets for the FOBT. Detection of these new targets in cancer cells 
constitutively shed in feces could increase the sensitivity of the FOBT and regress the stage at 
which the cancer is detected at less cost than DNA screening. Earlier detection would then 
cause a concomitant reduction in morbidity and mortality due to CRC.  
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Figure 3. Somatic mutations cause the progression of colon cancer. DNA damage 
converts normal colonic crypts to hyperplastic ACF. Subsequent somatic mutations confer a 
selective advantage on a subset of ACF, which then become benign growths known as 
adenomas or polyps. Cells in some adenomas sustain further somatic mutations which allow 
the growth to invade neighbouring tissue, at which point the lesion is called a carcinoma. 











1.3 Protein markers of colon cancer 
Proteins identified to date as markers of colon carcinogenesis lie in cellular 
proliferation pathways, DNA repair pathways, apoptosis pathways or vascularization 
pathways, congruent to features of colon cancer (Vogelstein & Kinzler, 2004). In high-risk 
populations, e.g. those with a first-degree relative diagnosed with colon cancer, candidate 
protein markers found in stool include immune-associated calprotectin, lactoferrin, and 
lysozyme, and serum proteins such as alpha-1-antitryps n, albumin, and transferrin 
(Loganayagam, 2008). Proteins previously shown to be upregulated in tumours include: Ki67, 
a ribosome assembly factor (MacCallum & Hall, 2000) whose expression correlates with 
cellular proliferation (Scholzen et al., 2002) and which  has been used as a biomarker in colon 
cancer (Fernandez-Cebrian et al., 2007); PCNA, a DNA replication fork component also 
upregulated during enhanced cellular proliferation and in tumours (reviewed in Semple & 
Duncker, 2004); and carcinoembryonic antigen (CEA), a cell adhesion protein which is only 
expressed in large quantities during fetal development and in tumour cells (Duffy et al., 
2007).  All tumour markers evaluated to date lack specificity, sensitivity or both, and 
therefore panels of markers are preferred (Duffy et al., 2007). The diversity of expression 
profiles in different cancers even within a tissue type also highlights the need for new 
biomarkers which could possibly be included in such panels. 
1.4 Nucleic acid markers of colon cancer 
Proteins are not the only molecular biomarkers of colon cancer. There are numerous 
gene mutations which are known to occur during the ACF-adenoma-carcinoma sequence of 
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events (Figure 3) and can provide targets for PCR amplification. Transformed cells shed in 
the feces contain mutated DNA sequences which can be detected via PCR (Duffy, 1995). 
Products of genes mutated in cancers participate in ma y cellular pathways, including 
apoptosis, DNA replication, mismatch repair, and tissue vascularization (Huerta, 2008), and 
their levels as well as levels of downstream  targets may be altered as a result. However, while 
a single mutation can be inexpensive to detect, colorectal tumours display on average 4-6 out 
of the hundreds of possible mutations (Fearon & Vogelstein, 1990), rendering mutational 
screening more costly than originally thought. Also, a functional protein product must be 
translated from an mRNA transcript for upregulation t  have an effect, and this translation can 
be modulated post-transcriptionally by the cell, leading to discrepancies between mRNA 
levels and phenotypic changes. These discrepancies render ideal target prediction much more 
difficult.  
 Non-protein markers of cellular proliferation have also included 3H-thymidine, a 
radioactively-labelled nucleotide, and BrdU (bromode xyuridine), a thymidine analogue to 
which antibodies are commercially available (Alberts e  al., 2002; McLellan et al., 1991a). In 
the presence of one of these thymidine substitutes, replicating cells will incorporate it in place 
of some thymidine residues during replication.  The level of detected thymidine substitute can 
therefore theoretically be used as a relative measur  of replication activity.  3H-thymidine has 
been used to assess proliferative characteristics of ACF, CRC cells and xenografts in studies 
of chemoprevention, diet effects  and treatments  as well as to contribute to prognosis 
predictions in post-resection biopsy (Costa et al., 1997; McLellan et al., 1991a; Tangpricha et 
al., 2005; Wang et al., 2007; Xie et al., 2006). However, since 3H-thymidine has recently been 
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shown to induce cell cycle arrest and apoptosis in cells, its validity in assessing DNA 
replication rates is questionable (Hu et al., 2002). 
BrdU has also been used to assess cellular proliferation rates in ACF-containing 
mucosa (Magnuson et al., 1994; Sutherland & Bird, 1994). When BrdU is applied by injection 
one hour prior to termination of previously AOM-challenged Sprague Dawley rats, resulting 
ACF appear to contain more BrdU-labelled cells than normal crypts (Magnuson et al., 1994), 
but there was no significant difference seen between th  number of BrdU-labelled cells per 
100 cells between those two crypt types (Magnuson et al., 1994; Sutherland & Bird, 1994).  
These results indicate that ACF contain more cells overall than normal crypts, but the same 
proportion of them are actively cycling.  This is consistent with the morphologically larger 
size of ACF at the tissue level, while not being particularly useful in supporting the prognostic 
value of ACF. It has been suggested that circadian rhythms may be a determining factor in 
cell proliferation and migration in colonic crypts, since functional “clock genes” are expressed 
there (Hoogerwerf et al., 2007). Recent research has suggested that stem cells increase in 
number as part of carcinogenesis in crypts (Boman et l., 2008) 
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1.5 DNA replication and the cell cycle 
 The utility of PCNA as a tumor marker was discovered prior to the elucidation of its 
role in DNA replication (Chan et al., 1983; Mathews et al., 1984). Since then, a much more 
detailed model of DNA replication in which many newly elucidated proteins play a regulatory 
role has been  constructed (Bell & Dutta, 2002) (Figure 4). The utility of many DNA 
replication factors, particularly those involved in replication initiation, as more sensitive 
tumour markers than traditional ones such as PCNA and Ki67 is currently being revealed (see 
Semple & Duncker, 2004 for a review). An overview of factors involved in DNA replication 
is presented below. 
 DNA replication occurs during S phase of the cell ycle (Figure 5). The accuracy of 
DNA replication prior to cell division is confirmed during G2 phase; nuclear (mitosis) and 
cytoplasmic division (cytokinesis) occur during M phase; and most factors necessary for the 
next round of DNA replication are assembled during G1 phase. Progression of each phase of 
the cell cycle is controlled via the regulation of activating kinases (Bell & Dutta, 2002). 
 DNA replication is initiated by mitogen signaling which induces the expression of 
immediate early genes such as fos, jun & myc (Masai et l., 2005). Immediate early gene 
products lead to expression of cyclin D which activates Cdk4 enabling it to phosphorylate the 
retinoblastoma (Rb) protein (Masai et al., 2005). Phosphorylation of Rb releases previously 
bound E2F transcription factor (Masai et al., 2005). Unbound E2F induces the transcription of 
replication factors such as the S-phase cyclins E and A, the Cdc7-activating protein, ASK 
(associated with S-phase kinase), and subunits of MCM helicase (Kim et al., 2003; Masai et 
al., 2005). The origin recognition complex (ORC), in cooperation with other factors, 
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effects the loading of MCM helicase onto origins of replication during G1 phase in an ATP-
dependent event (Bell & Dutta, 2002).  Activation of MCM, the final step in late G1 before 
DNA replication can begin, is accomplished via phosphorylation of MCM subunits by 
Cdc7/ASK, the activity of which has been demonstrated in vitro to be enhanced by prior 
MCM phosphorylation by Cdk2/cyclinE (Kim et al., 2003; Masai et al., 2000; Masai et al., 
2005). Changes in MCM conformation then allow recruitment of Cdc45 and GINS forming a 
complex known as CMG which is capable of processive unwinding of DNA (Sclafani & 
Holzen, 2007). In budding yeast, CDKs additionally promote DNA replication initiation by 
phosphorylating Sld2 and Sld3, both of which are required for initiation (Zegerman & Diffley, 
2007). Phosphorylation of MCM subunits by S-phase CDKs negatively regulates re-initiation 
by blocking MCM loading once activation is accomplished (Masai et al., 2005; Sclafani & 
Holzen, 2007). 
Unwinding of origin DNA by the CMG complex produces single-stranded DNA which is 
prevented from re-annealing by the single-stranded DNA-binding protein replication protein 
A (RPA) (Moldovan et al., 2007).  A DNA-dependent RNA polymerase called primase, 
complexed with DNA polymerase α, is recruited to DNA by CMG-associated factors Mcm10 
and And-1 (Zhu et al., 2007). Primase synthesizes a short stretch of RNA complementary to 
origin DNA which is then extended with DNA complementary to the next ~30 nucleotides by 
DNA polymerase α (Stillman, 2008). The 3′ end left by termination of synthesis by DNA 
polymerase α attracts replication factor C (RFC) (Moldovan et al., 2007). RFC, in cooperation 
with RPA, acts as a clamp loader to load PCNA onto the single strand (Sclafani & Holzen, 
2007). PCNA is a homotrimeric sliding clamp ring responsible for tethering DNA 




Figure 4. Initiation of DNA replication. A. DNA replication initiation begins with 
binding of ORC and its associated factors (green) to origins of replication. These factors 
then effect the loading of MCM helicase (light blue) onto double-stranded DNA. MCM is 
activated by phosphorylation by Cdc7/ASK (red oval). Pink star indicates the site of MCM 
phosphorylation (Masai et al., 2005). B. Activated MCMs, in concert with Cdc45 and the 
GINS complex (not shown), begin to unwind origin DNA in a bidirectional fashion 
(Sclafani & Holzen, 2007). RPA (red circles) binds the single-stranded DNA accumulated 
behind the helicase to prevent re-annealing (Moldovan et al., 2007). Block arrows indicate 
direction of unwinding. C. Short (20-22 nt) primers are laid down by the primase/DNA 
polymerase α complex (yellow) (Moldovan et al., 2007). Block arrows indicate direction of 
primer synthesis. D. The 3′ end of primers is the site where PCNA (purple) is loaded 
Moldovan et al., 2007). PCNA then recruits the replicative DNA polymerases ε (leading 
strand, shown at bottom) and δ (lagging strand, shown at top) (orange rectangles) and 












Primase/DNA polymerase α complex 
PCNA DNA polymerase δ 








Figure 5. Phases of the cell cycle. The cell cycle consists of 
four phases: G1, S, G2, and M. Transition between th  
respective phases is accomplished via regulation of kinase 
activation (Bell & Dutta, 2002). DNA replication occurs during 
S phase, but factors involved in its inititation can be loaded 




 DNA synthesis (Moldovan et al., 2007). Once PCNA has attracted the replicative 
polymerases to DNA, elongation is effected by the concerted effort of the complete replisome, 
including MCM helicase, PCNA, and the DNA polymerases. Thus, Cdc7 functions as an 
essential regulator of S-phase entry and PCNA participates as part of the replication complex 
during the elongation process once S-phase is initiated. 
1.6 DNA damage detection and repair  
Damage to the DNA template can lead not only to defects in gene products but also to 
errors in replication which can jeopardize genome int grity. Tumours detected through the use 
of biomarkers arise as a major consequence of the failure of the DNA damage response to 
prevent chromosomal instability and mutation. Because DNA damage can pose a serious 
threat to cellular viability, cells have evolved multiple mechanisms to detect and repair such 
damage (Branzei & Foiani, 2008; Kastan & Bartek, 2004; Moldovan et al., 2007).  DNA 
damage can be caused by ionizing radiation, errors in replication, or exposure to chemical 
carcinogens (Kastan & Bartek, 2004). Popular chemical carcinogens used in rat models of 
colon cancer are typically precursors of the DNA alkylating agent methylazoxymethanol 
(MAM), and include dimethylhydrazine and its metabolite AOM (Sohn et al., 1991). DNA 
alkylation resulting from carcinogen challenge is as ociated with sister chromatid exchange, 
gene mutations and chromosome rearrangements in mammals. The size of the alkyl adduct 
determines which repair mechanism will be employed (Kastan & Bartek, 2004). Simple 
methyl adducts can often be excised by an enzyme called methylguanine DNA 
methyltransferase (Sancar et al., 2004). More bulky DNA alkylations cause fork stalling and 
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trigger more complex DNA repair mechanisms such as base excision repair (Sancar et al., 
2004). Furthermore, extensive methylation or alkylation can lead to DNA crosslinking and 
DNA double-stranded breaks (DSBs) (Sancar et al., 2004). Sensing of DNA damage during 
replication involves pathways known as cell cycle ch ckpoints (for reviews, see Branzei & 
Foiani, 2005; Branzei & Foiani, 2009; Kastan & Bartek, 2004; Sclafani & Holzen, 2007).  
There are two cell cycle checkpoint pathways, named after the PI(3)K-like kinases 
(PIKKs) associated with their initiation: the ataxi telangiectasia mutated (ATM) pathway, 
which is activated in response to double-stranded br ak damage, and the ataxia telangiectasia 
and Rad3-related (ATR) pathway, induced by fork stalling and single-stranded breaks (SSBs), 
including those SSBs which are formed as an intermediat  product of DSB repair (Branzei & 
Foiani, 2008; Branzei & Foiani, 2009; Kastan & Bartek, 2004; Matsuoka et al., 2007).  Of the 
two PIKKs, only ATR is essential for viability, due in part to its important roles in promoting 
fork stability and monitoring fork progression during normal replication (Kastan & Bartek, 
2004).  ATM and ATR exert their effects through theactivation of effector kinases known as 
Chk2 and Chk1 respectively (Kastan & Bartek, 2004). 
There is evidence that Cdc7 is involved in the ATR–mediated response to fork stalling 
in human cancer cells and mouse embryonic stem cells (Kim et al., 2008; Tenca et al., 2007). 
Damage-induced fork stalling causes polymerase to pause while helicase continues to unwind 
DNA, leading to extended stretches of exposed single-stranded DNA (Branzei & Foiani, 
2005; Branzei & Foiani, 2009; Zegerman & Diffley, 2009). The presence of large stretches of 
single-stranded DNA serves as a signal to recruit ATR to stalled forks at which PCNA-
associated Chk1 (Scorah et al., 2008) and the mediator protein claspin are normally bound 
(Zegerman & Diffley, 2009). Cdc7, which is active during perturbed S phase (Tenca et al., 
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2007), phosphorylates claspin, activating it and thus enabling claspin-mediated Chk1 
activation by ATR (Kim et al., 2008) (Figure 6).  It is not known whether Cdc7 levels are 
increased in association with this function; however relatively constant levels of Cdc7 are 
present during the normal cell cycle (Masai et al., 2005), suggesting that short-term 
fluctuations in Cdc7 levels can be attributed to other functions such as DNA damage 
signaling. Chk1 activation then prevents the onset of mitosis, firing of late origins, and fork 
collapse (Kastan & Bartek, 2004; Kim et al., 2008). 
 Interestingly, checkpoint inhibition of  late origin firing in yeast is accomplished in part by 
impeding Cdc7 activity through phosphorylation of the yeast ASK  homologue, Dbf4 
(Branzei & Foiani, 2005; Costanzo et al., 2003; Kastan & Bartek, 2004). ASK itself is an i
vitro target of Chk1 kinase activity as well as interacting with Chk1 in vivo in human cells in 
response to UV irradiation, suggesting that ASK may be a target of Chk1 activity during 
checkpoint response (Heffernan et al., 2007). Since Cdc7 remains active following checkpoint 
initiation (Tenca et al., 2007), inibition of late origin firing may be accomplished simply by  
disengaging ASK from origins, while levels of active Cdc7 remain the same or increase due 
to upregulation of non-origin-bound Cdc7 in response to ATR signaling. 
Sometimes, fork collapse cannot be averted by the ATR-Chk1 signal. In the event of 
fork collapse, PCNA associated with the replisome is modified by SUMO or ubiquitin 
(Branzei & Foiani, 2005; Moldovan et al., 2007). These modifications are thought to release 
DNA polymerase δ or ε from PCNA and increase its affinity for alternative DNA polymerases 
(Branzei et al., 2008; Moldovan et al., 2007), such as polymerases κ, ι, and η, each of which 
contains a unique pocket designed to accommodate a sp cific type of lesion (Moldovan et al., 
2007).  Following PCNA-mediated repair, it is not known whether PCNA is deubiquitylated 
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Figure 6. Cdc7 is involved in claspin-mediated ATR signaling. In response to fork stalling, 
ATR phosphorylates the mediator protein claspin. Recent evidence suggests that Cdc7/ASK also 
phosphorylates claspin as part of its activation (Kim et al., 2008). Activated claspin mediates the 
activation of Chk1 kinase by ATR (Kastan & Bartek, 2004). This effector kinase then acts on 




or replaced by a new, unmodified moiety (Moldovan et al., 2007). If modified PCNA must be 
replaced, expression of PCNA is likely upregulated to make the substitution. In the event that 
the lesion is not passable by alternative polymerases, template switching may be initiated, also 
mediated by PCNA (Moldovan et al., 2007). Because PCNA-mediated repair processes 
follow fork collapse which follows ATR signaling, upregulation of PCNA to supply restarting 
forks should follow upregulation of Cdc7 during chekpoint initiation. 
Sometimes, even the elegant DNA damage response machinery in the cell is insufficient 
to avert permanent changes in the DNA sequence. Depending on their location and extent, 
such mutations may cause no phenotypic changes; they may cause minor, benign phenotypic 
changes; they may cause the cell to become non-viable; or they may complete a set of 
previous mutations, resulting in a cancerous cell. 
1.7 Cdc7 and PCNA as cancer biomarkers 
 There is some evidence that Cdc7 levels are increased in tumour cells relative to those 
in normal tissues (Bonte et al., 2008; see also Hess et al., 1998; reviewed in Semple & 
Duncker, 2004). Cdc7 was originally suggested as a potential cancer biomarker in mRNA 
studies of multiple tissue types and cell lines (Hess t al., 1998). Several other replication 
initiation proteins, including some MCM subunits, have previously been shown to be more 
sensitive markers of abnormal cells in some cancers than either PCNA or Ki67 (see Semple & 
Duncker, 2004 for a review). More recently, Cdc7 protein levels have been shown to be 
upregulated in human colon and breast cancer tissues and in multiple cancer cell lines (Bonte 
et al., 2008) as well as in melanoma (Clarke et al., 2009).  Cdc7 additionally has prognostic 
value in assessing potential morbidity due to ovarian carcinoma (Kulkarni et al., 2009).  
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Small-molecule inhibitors of Cdc7 kinase activity are now being developed as novel cancer 
treatments, which have the advantage of both impeding replication initiation and obstructing 
the DNA damage response which cancer cells rely on to avoid lethal mutations 
(Menichincheri et al., 2009; Montagnoli et al., 2008; Vanotti et al., 2008). 
PCNA has been ubiquitously employed as an immunohistochemical marker of cellular 
proliferation in most cancers, including hepatocellular carcinoma (Shen et al., 2008), gastric 
cancer (Li et al., 2008), and colon cancer (Baijal et al., 1998). Evidence has been presented 
which indicates that PCNA may not accurately reflect the early development of precancerous 
lesions.  Sutherland and Bird (1994) investigated the effect of chenodeoxycholic acid (a bile 
acid purported to promote cancer) on the development of ACF as a result of AOM injection. 
The percentage of cells staining positive for PCNA (“labelling index”) was the same or 
slightly higher in colons of animals not exposed to carcinogen, indicating that PCNA 
expression may actually be decreased in precancerous stages, although possibly not to an 
extent which is useful for detection. PCNA labelling i dex is also not independent of the 
presence of exogenous bile acids even without carcinogen challenge (Baijal et al., 1998), 
suggesting that the presence of PCNA may indicate pthologies not related to carcinogenesis. 
This may be due in part to upregulation of PCNA following some forms of successful DNA 
damage repair (reviewed in Moldovan et al., 2007) (see section 1.6). 
1.8 Predisposition of overweight and obese animals to colon cancer 
Obesity complicates the picture of cancer. Disorders associated with obesity such as 
hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and diabetes all show 
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comorbidity with CRC (Campbell & McTiernan, 2007).  Obesity-associated visceral 
abdominal fat is positively correlated with putative preneoplastic lesions (Takahashi et al., 
2009). Obese animals are at greater risk than lean animals of developing tumours in response 
to AOM administration (Eskin et al., 2007; Raju & Bird, 2003; Weber et al., 2000).  
Increased CRC risk in obese animals appears to be larg ly due to inhibition of DNA 
damage response coupled with enhanced cellular proliferation. Cytokines expressed by 
adipocytes promote colon carcinogenesis and inhibit DNA repair by enhancing inflammation 
and nitrosylating damage response enzymes (Jaiswal et al., 2000; Mena et al., 2009). 
Saturated fatty acids, which are much more plentiful in obese animals, have also been shown 
to inhibit the DNA damage response in untransformed cells, through unclear mechanisms 
(Zeng et al., 2008). Increased cellular proliferation signaling affects normal and tumour 
tissues causing tumours to grow faster in obese animals. Hyperinsulinemia and high blood 
glucose levels commonly seen in obese populations augment cellular proliferation in the 
colon (Mena et al., 2009). Tumour cells appear to induce expression of some cancer-
promoting factors in neighbouring adipocytes and fibroblasts, leading to enhanced tumour 
growth in adipocyte-rich obese animals (Motrescu & Rio, 2008). Hence, obesity leads to 
impairment of the DNA damage response resulting in increased risk for mutation, and 
enhanced cellular proliferation signaling subsequently leads to augmented tumour growth. 
1.8.1.a Animal models of obesity 
 Increased risk for development of colon cancer has been demonstrated in both obese 
mice and obese rats (Ealey et al., 2008; Kobayashi et al., 2000; Raju & Bird, 2003). The 
Zucker obese (fa/fa) rat resulted from a spontaneous autosomal recessive mutation in a cross 
between Sherman rats and the 13M strain of Rattus norvegicus (Argiles, 1989; Bray, 1977).  
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Originally designated the fa (fatty) gene, the mutation was later discovered to be a loss-of-
function mutation in the leptin receptor, causing a lack of sensitivity in the recessive 
homozygote to satiety signaling (Argiles, 1989). Together with its lean (Fa/Fa or Fa/fa) 
counterpart, the Zucker obese rat model has greatly facilitated studies of the etiology of 
obesity as well as the interaction between obesity and disorders such as hypertension 
(Dakshinamurti et al., 1998; Kanda et al., 2006; Kim et al., 1994; Namikoshi et al., 2008),  
insulin resistance (Deushi et al., 2007; Kiunga et l., 2004; Whaley-Connell et al., 2008; 
Zhang et al., 2007), hepatic steatosis (Deushi et al., 2007; Raju & Bird, 2006), and even 
erectile dysfunction (Wingard et al., 2007). The obse Zucker rat’s inherent hyperinsulinemia, 
enhanced cellular proliferation and general metabolic syndrome are associated with increased 
risk for development of tumours (Koch et al., 2008; Raju & Bird, 2003; Raju et al., 2006; 
Weber et al., 2000). It is therefore a credible model to study the differences between obese 
and lean animals during colon carcinogenesis (Raju & Bird, 2003; Raju et al., 2006).   
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1.9 Objectives and hypotheses 
The purpose of this work was to investigate the relationships between Cdc7 expression, 
PCNA expression, colon carcinogenesis and obesity in a rat model.  The main objective of 
this research was to assess expression levels of Cdc7 and PCNA during early and late stages 
of colon carcinogenesis to determine their utility as markers of early and late events. 
We specifically hypothesized that: 
1. Since Cdc7 is involved in ATR checkpoint activation (Figure 6) and PCNA 
upregulation occurs following DNA damage repair (see ction 1.6 in the 
Introduction), Cdc7 protein levels should peak prior to PCNA levels during the 
first 24 hours following AOM administration. Changes in Cdc7 levels are 
expected to be due to non-cell-cycle roles since Cdc7 levels are relatively 
constant throughout the cell cycle in normal cells. 
2. As a result of increased proliferation signaling over their lean counterparts, 
Zucker obese rats should show elevated Cdc7 and PCNA levels in mucosa 
relative to lean by the time tumours appear. 
3. Both Cdc7 and PCNA protein expression will be higher in Sprague Dawley rat 
tumours compared to normal-appearing mucosa, as shown previously in human 
mRNA studies for Cdc7 and multiple studies for PCNA. 
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To test these hypotheses, colonic tissues were collcted for three different studies:  
Study 1:  Zucker obese and lean rats were used to model of the effect of obesity 
on Cdc7 and PCNA expression during colon carcinogenesis (see section 1.8). 
Animals were injected with the carcinogen AOM and tissues were analysed for 
Cdc7 and PCNA levels 3, 9 and 24 hours post-injection; 
Study 2: Obese and lean rats injected with AOM were allowed to develop 
tumours. Tumours and normal-appearing colonic mucosa llected 32 weeks 
post-AOM were then assessed for Cdc7 and PCNA levels; 
Study 3: Sprague Dawley male rats, an experimental model commonly used to 
study colon carcinogenesis, were injected with AOM. Colonic tumours were 
assessed for Cdc7 and PCNA levels and compared to those of normal-appearing 




Chapter 2.  Materials and Methods 
2.1 Rat strains 
 Two strains of Rattus norvegicus were used during this study: Zucker, a genetically 
obese rat homozygous recessive for a nonfunctional leptin receptor, together with its lean 
(homozygous dominant/heterozygous) counterpart; and Sprague Dawley, a non-obese, 
common laboratory rat.  
2.1.1 Zucker 
Thirty-five obese (fa/fa) and forty lean (Fa/Fa or Fa/fa) seven-week-old female Zucker rats 
were acquired from Charles River Laboratory (Wilmington, MA).  All animals were housed 
in wood-shaving-lined plastic cages with stainless straight wire lids designed to accommodate 
food and water delivery. Animals were allowed to acclimate to the animal housing facility 
(Biology Department, University of Waterloo) for 10days, during which time they were fed 
standard lab chow (modified AIN-76A, Harlan Teklad). A uniform temperature of 22°C and 
humidity of 55% were maintained in the animal housing facility. Following acclimation, all 
but 12 (6 obese and 6 lean) were challenged with a single dose of AOM at 10 mg/kg, 24h, 9h, 
or 3h prior to termination (Figure 7).  A reduced dose relative to that used for Sprague 
Dawley rats was delivered to the Zucker rats to allw for possible increased toxicity of AOM 
in Zucker obese rats (Eskin et al., 2007). All Zucker obese and lean rats involved in Study 1 
(see Objectives and hypotheses) were terminated concurrently. The remaining five obese and 











Figure 7. Experimental design for Zucker studies (Study 1 and Study 2). Groups of obese 
and lean rats were either left uninjected or injected with AOM 24h, 9h, or 3h prior to the first 
termination (0h). An additional  group of rats of each obese phenotype were additionally injected 
with AOM at the -3h timepoint; these animals were terminated 32 weeks post-AOM. Tumours 
were excised from 32-week specimens, and all mucosa were collected. Tissue samples were 
snap-frozen in liquid nitrogen and stored at -80°C pending western blot sample preparation. 
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2.1.2 Sprague Dawley 
Tissues from male Sprague Dawley rats terminated for a previous study (Begleiter et 
al., 2003) were used for Study 3. Six-week old male Sprague Dawley rats were previously 
appropriated from the University of Manitoba Central Animal Care Breeding Facility. The 
animals were originally fed a modified AIN-76A (American Institute of Nutrition-76A) 
powdered diet (Harlan Teklad) with 13% dextrose and 52% cornstarch, challenged with the 
colon-specific carcinogen AOM at 15mg/kg in two weekly doses, and terminated at 32 weeks 
post-challenge (Figure 8). Colons were previously removed, flushed with 0.9% saline and slit 
lengthwise. Mucosa was scraped away from muscularis, snap-frozen in liquid nitrogen, and 
stored at -80°C. 
All animals were cared for according to the guidelin s of the Canadian Council on 
Animal Care, and the experimental protocol was approved by the University of Waterloo 











Figure 8. Experimental design for Sprague Dawley study (Study 3). Sprague-Dawley 
rats were given two injections of AOM one week apart. Animals were terminated 32 
weeks later, tumours were excised and mucosa collected. All samples were snap-frozen 
in liquid nitrogen and stored at -80°C until samples were prepared for Western blot. 
31 
 
2.2 Tissue collection 
Colons were removed, flushed and slit lengthwise as for Sprague Dawley rats.  
Tumours were excised from the mucosa using scissors and placed in labelled 1mL capped 
plastic tubes (Eppendorf). Mucosa was scraped away from muscularis and placed in similar 
labelled tubes. All tissues were snap-frozen in liquid nitrogen and stored at -80°C. Five 
mucosal samples were randomly chosen from the final te  lean Zucker rats for inclusion in 
Study 2. 
2.3 Tissue homogenization and extraction of soluble proteins 
 Frozen mucosa and tumours were sliced thinly then chopped into fine pieces on a 
fresh Petri dish at 4°C using a clean razor blade. Each sample was then dropped into a 
labelled glass test tube containing 4mL modified RIPA buffer (50mM Tris; 1% NP-40; 0.25% 
sodium deoxycholate; 150mM NaCl; 1mM EDTA; 1mM NaF; 1mM sodium orthovanadate; 
1mM PMSF) per gram of tissue, rounded up to the nearest 1mL. Test tubes were kept covered 
with Parafilm® (American National Can Company) when not in use. Tissues (still in buffer) 
were homogenized on ice using a Polytron® PT-2100 disperser (Kinematica) with a 12mm 
aggregate twice for 15 seconds each, cooling for at least 30 seconds in between. Resulting 
homogenates were then removed to labeled, capped 1mL Eppendorf tubes and spun at 4°C 
using a refrigerated centrifuge (Eppendorf 5415R) for 15 minutes at 16.1g to pellet the 
insoluble proteins and float the lipids.  The clearest part of the liquid layer between the pellet 
and lipids was removed to a fresh labeled 1mL Eppendorf tube. A portion of each resulting 
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sample was assayed using the Bradford method to determine total protein concentration. On 
the basis of these concentrations, western blot samples were made up containing 50µg total 
protein using 1:1 protein extract:2X Laemmli buffer  (Sigma). 
2.4 Western Blot 
Protein extracts from colonic tumour samples and samples from adjacent colonic 
mucosae of male Sprague Dawley rats treated with AOM and terminated after 32 weeks were 
analyzed by Western blot for the presence of Cdc7 and PCNA, with HeLa cell lysate (Santa 
Cruz) as a positive control, using established labor tory protocols. 
 Electrophoresis of samples prepared for western blot was accomplished using the 
equipment and methods of the Mini-Protean III and Mini Trans-blot systems (BioRad). 
Briefly, 8% polyacrylamide resolving gels with 6% stacking gels were loaded with one 
sample per lane, including one HeLa positive control (Santa Cruz) and at least one molecular 
weight marker (Sigma or Fermentas) for each gel and were electrophoresed at 120V for at 
least 90 minutes (until the dye front had progressed to near bottom of gel, and the marker for 
molecular weight closest to that of Cdc7 (64kDa) had migrated to the middle of the gel). 
Electrophoretic transfer to nitrocellulose membranes was then performed at 100V for one 
hour, using a Mini Trans-Blot® wet transfer unit (BioRad) and Buffer A (25mM Tris, pH 8.3; 
192mM glycine, 20% methanol and 0.05% sodium dodecyl sulfate (SDS)). 
 Membranes were rinsed twice with distilled water to emove transfer buffer then 
immersed in 0.1% Ponceau S in 5% acetic acid for 1 hour to stain total proteins. Following 
Ponceau staining, membranes were removed to distilled water for 2-5 minutes to remove 
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excess stain and improve contrast between membrane-ound block alone and total cellular 
proteins. They were then drained by dabbing a corner o  a Kimwipe and placed face down on 
a scan bed (Epson). To remove bubbles from between the membrane and the scan bed, the 
membrane was rolled gently with a glass rod. A digital image of the Ponceau-stained 
membrane was acquired at 300 dpi in colour. If protein lanes did not contrast sufficiently with 
background, the membrane was placed in a second trough f fresh distilled water, and the 
scan was repeated to ensure the clearest representation of the relative amount of total protein 
in each lane. Membranes were then washed twice for five minutes by gentle rocking in T-TBS 
wash buffer (0.02M Tris pH 7.5; 0.15M NaCl; 0.05% Tween-20) to remove remaining 
Ponceau stain and blocked in 25mL 5% skim milk in T-TBS for 1 hour at room temperature 
or overnight at 4°C. Membranes were then incubated with polyclonal rabbit Cdc7 antibodies 
(Santa Cruz) in 1% skim milk/T-TBS at a dilution of 1:200 (10mL per membrane) for 105 
minutes at room temperature or overnight at 4°C, rocking gently. After three vigorous washes 
in T-TBS, horseradish peroxidase (HRP)-conjugated secondary antibody at a dilution of 
1:3000 in 1% skim milk/T-TBS was applied by gentle rocking for 1h at room temperature. 
Membranes were then washed vigorously three times in T-TBS, and visualization of binding 
location and quantity of secondary antibody was achieved via chemiluminescent substrate 
(ECL-Plus, GE Healthcare). Membranes were then washed gently in T-TBS for five minutes, 
re-blocked to ensure minimal background noise caused by nonspecific binding of the antibody 
to the membrane, and detection was repeated as above using monoclonal mouse PCNA 
antibodies (Cell Signaling Technologies) at a dilution of 1:2000 and HRP-conjugated anti-
mouse secondary at a dilution of 1:3000. For Study 1 and Study 3, blots were then reprobed 
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using the same methodology with polyclonal goat Mcm2 antibodies (Santa Cruz) at a dilution 
of 1:200 and HRP-conjugated anti-goat secondary at a dilution of 1:10000. 
2.5 Densitometry and statistical analysis 
 In order to assess whether Cdc7 and PCNA protein levels differed between groups on 
a particular blot, ImageJ (Rasband, 1997-2009) was used to assess the mean gray value on a 
rectangle of constant size encompassing each band in turn. The corresponding Ponceau-
stained image was then converted to 8 bit grayscale, and the mean gray value of a different 
rectangle of constant size encompassing a thin sample of the entirety of each lane was 
measured. The Ponceau values were used to normalize the bands to correct for possible 
differences in total protein loading between lanes which might occur due to inaccuracy of the 
Bradford assay. In the event that a single blot would not accommodate all desired groups, 
each group was divided evenly between blots. Half of each group appeared on each blot, to 
evenly distribute between-blot variation across all groups. HeLa cell lysate was used to 
normalize between blots prior to statistical analysis. All comparisons were done using Excel 
to perform the Student’s t-test and assuming unequal variances.
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Chapter 3.  Results 
3.1 Animal weights 
 Zucker rats were weighed at the time of termination o compare obese rat weight to 
that of their lean counterparts at early and late termination times (see Figure 7). Lean and 
obese rats terminated during the first 24h post-AOM injection (Study 1) weighed 
approximately 148g and 268g, on average, respectively, while those terminated at 32 wks 
post-AOM injection (Study 2) weighed approximately 260g and 722g on average, 
respectively (Figure 9). Obese rats were significantly heavier than their lean littermates both 
immediately following AOM injection and at the time tumours appeared. However, 
significantly greater weights for both obese and lean rats at the late timepoint than the early 
timepoint indicates the rats were still engaged in evelopmental growth. 
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Figure 9. Obese rats are significantly heavier than age-matched lean 
rats at both termination timepoints. Obese 8-week-old rats (early 
events) were similar in weight to lean 39-week-old rats, highlighting the 
difference in the phenotype. Values are means ± standard deviation. 
Bars with different letters (α, β or γ) represent weight values which are 






















3.2 Study 1: Early events in colon carcinogenesis in Zucker obese and lean 
rats 
3.2.1 Cdc7 levels are increased in lean colonic mucosa relative to obese by 3h post-
AOM 
Since Cdc7 levels are relatively constant throughout the cell cycle (Masai et al., 2005), 
we reasoned that any difference in Cdc7 protein level between obese and lean colon 
immediately following DNA damage should be attributable to impairment of the DNA 
damage response in the obese state. We therefore assessed Cdc7 levels in obese and lean 
colon 3h, 9h and 24h after carcinogen administration as well as in age-matched uninjected 
animals (Figure 10-Figure 13). 
The Cdc7 antibody consistently generated two bands in both the HeLa positive control 
and the rat samples: a strong band at approximately 64kDa (consistent with the theoretical 
respective weights of human and rat Cdc7 which are 64kDa and 62kDa); and a fainter co-
migrating band at approximately 84kDa. Previous studies have demonstrated multiple co-
migrating bands in human samples using the same antibody, which were unaffected by siRNA 
depletion of Cdc7, suggesting that bands which do not appear near 64kDa are not the product 




Figure 10. No significant differences were seen in Cdc7 or PCNA expression between 
the colonic mucosa of obese and lean uninjected Zucker rats. Whole soluble protein 
extracts from colonic mucosa of unchallenged Zucker obese and lean rats were homogenized 
in modified RIPA buffer and soluble proteins were extracted by centrifugation (see 
Materials and Methods). Cdc7 and PCNA protein levels were detected by immunoblotting. 
Densitometric quantitation of resulting bands was normalized to that of total protein 
(measured by Ponceau S staining) for each sample. Resulting values averaged over total 
number of samples are shown graphically as means ± standard deviation (nobese=5; nlean=6). 





































































Figure 11. Higher Cdc7 levels in the colonic mucosa of lean relative to obese rat colonic 
mucosa 3h post-carcinogen challenge is consistent with checkpoint-associated 
upregulation of Cdc7 favoured in lean rats. Whole soluble protein extracts from mucosa of 
challenged Zucker obese and lean rats collected 3 hours after AOM challenge were prepared 
as for uninjected Zucker rats (see Figure 10). Cdc7 and PCNA protein levels were detected by 
immunoblotting. Densitometric quantitation of resulting bands was normalized to that of total 
protein (measured by Ponceau S) for each sample. Resulting normalized measurements were 
averaged over the total number of samples in each group and are shown graphically as means 
± standard deviation  (nobese=6; nlean=6). Densitometry was performed using Image J software 
(NIH). Asterisk (*) indicates significant difference between obese and lean (p<0.05). PCNA 






































































Figure 12. No significant difference in Cdc7 or PCNA expression was seen in the colonic 
mucosa of lean relative to obese rats 9h post-carcinogen challenge. Whole soluble protein 
extracts from colonic mucosa of challenged Zucker obese and lean rats collected 9 hours after 
AOM challenge were prepared as for previous Zucker rats (see Figure 10, Figure 11). Cdc7 
and PCNA protein levels were detected by immunoblotting, and resulting bands were 
quantified by densitometry. Resulting measurements were normalized to that of total protein 
(measured by Ponceau S staining) for each sample and averaged over the total number of 
samples in each group. Normalized protein levels are shown graphically as means ± standard 





































































Figure 13. Higher PCNA levels in lean relative to obese rat colonic mucosa 24 hours after 
DNA damage is consistent with PCNA role in DNA damage repair favoured in lean rats. 
Whole soluble protein extracts from colonic mucosa f challenged Zucker obese and lean rats 
collected 24 hours after AOM challenge were prepared s for previous Zucker rats (see Figure 
10-Figure 12). Cdc7 and PCNA protein levels were detected by immunoblotting, and resulting 
bands were quantified by spot densitometry. Measurements obtained were normalized to that 
of total protein (measured by Ponceau S staining) for each sample and averaged over the total 
number of samples in each group. Normalized levels are shown graphically as means ± 
standard deviation (nobese=5; nlean=6). Densitometry was performed using Image J software 











































































          No significant difference between lean and obese mucosal samples in Cdc7 or PCNA 
levels were seen (Figure 10), although statistical rends were toward increased Cdc7 in obese 
rat colonic mucosa (p~0.11) and decreased PCNA in obese rat colonic mucosa (p~0.13) 
relative to lean rat colonic mucosa. High variability between subjects from the same group 
was noted. These animals were female and were not necessarily on a common ovulatory 
cycle. It is possible that cyclic variation in hormone levels caused natural variability in levels 
of these proteins. It is noteworthy that no significant upregulation of either Cdc7 or PCNA 
was seen in colonic mucosa of obese rats relative to lean rats prior to AOM administration. 
Since tissues of obese animals are known to have higher proliferation rates (Mena et al., 
2009), it is reasonable to believe that obese colon w uld express significantly more cell cycle 
proteins, including both Cdc7 and PCNA, than lean colon. Possibly, Cdc7 expression 
differences are not as pronounced in growing rats due to globally enhanced proliferation in 
tissues of both groups relative to other stages of development. That the two replication factors 
showed opposing trends suggests that an increase in Cdc7 level in response to proliferation 
signaling alone is not necessarily accompanied by concomitant upregulation of PCNA. 
Whether this uncoupling of expression is due to more efficient degradation of PCNA or as a 
result of Cdc7 functions not involving PCNA is unclear.  
In contrast to uninjected animals, Cdc7 levels were increased in lean animals relative 
to obese as early as 3h post-AOM (Figure 11), suggesting that upregulation of Cdc7 in 
response to DNA damage occurs at a relatively early timepoint. PCNA levels were not 
significantly different between lean and obese rat colonic mucosa in uninjected rats. 
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Cdc7 upregulation at 3h post-AOM was only discernible through comparison of lean 
and obese animals, as neither the lean nor the obese Cdc7 expression time course showed 
significant differences between timepoints (see Figure A 1 and Figure A 2 in the Appendix), 
possibly due to smaller sample size used to create the time courses (n=5-6 vs n=3 per group). 
Non-significant trends in patterns of expression in these time courses showed a drop in Cdc7 
expression in obese rat colonic mucosa (p~0.08) which was not seen in lean. This suggests 
that differences in Cdc7 level seen at 3h post-AOM between obese and lean colonic mucosa 
could be the result of combined inhibition of Cdc7 expression to prevent origin firing during 
fork stalling in both rat phenotypes and concomitant or immediately subsequent upregulation 
of Cdc7 to support a more robust checkpoint signaling response in lean animals. 
3.2.2 PCNA levels are not significantly higher in lean colonic mucosa relative to obese 
until after 9 hours post-AOM 
By 9 hours post-AOM, significant differences between obese and lean rat mucosal 
levels of Cdc7 had reverted (Figure 12), suggesting that upregulation of Cdc7 in association 
with checkpoint initiation is transient. Obese and lean rat colonic mucosal PCNA level 
differences at this timepoint remained statistically non-significant, suggesting that PCNA 
upregulation is not required for early checkpoint processes.  
In contrast to Cdc7, PCNA levels were significantly increased in lean animals relative 
to obese at the 24 hour timepoint following DNA damage (Figure 13), indicating that PCNA 
upregulation during the DNA damage response occurs well after the initial rise in Cdc7. This 
is consistent with Cdc7 involvement in early checkpoint events and increased expression of 
PCNA following successful DNA damage repair. Similar to results for Cdc7 levels, PCNA 
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upregulation was detected only when lean rat colonic mucosa was compared to obese, as 
PCNA levels did not differ significantly between timepoints for either obese or lean (see 
Figure A 1 and Figure A 2 in the Appendix). Again, the lack of significant differences is 
possibly due to insufficient sample size in the timecourse experiments (n=5-6 vs. n=3 per 
group). Non-significant trends in PCNA levels in these timecourse experiments show a less 
dramatic increase between 9h and 24h post-AOM in obese rat colonic mucosa (p~0.13) than 
lean rat colonic mucosa (p~0.10), supporting impairment of obese DNA damage repair 
regulatory systems.  
3.3 Study 2: Late events in colon carcinogenesis in Zucker obese and lean 
rats 
3.3.1 Cdc7, but not PCNA, abundance is significantly higher in obese colon mucosa 
relative to lean late in carcinogenesis 
In order to examine the relative abundance of Cdc7 and PCNA in tumours in an obese 
rat model, the remaining Zucker rats were sacrificed at 32 weeks post-AOM. Unfortunately 
for statistical purposes, only 1 tumour was collected from the remaining 10 lean Zucker rats. 
Five obese Zucker rats produced a total of 6 tumours among them, thus clearly demonstrating 
the increased risk of CRC in obese animals.   
 Since obese rats are at higher risk to develop tumours and they have higher numbers 
of and larger ACF than lean rats late in carcinogenesis (Raju & Bird, 2003), it was 
hypothesized that obese animals would have increased mucosal hyperplasia relative to lean 
animals, causing a concomitant upregulation in replication factors such as Cdc7 and PCNA. 
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Cdc7 and PCNA levels were assessed by western blot in obese vs. lean Zucker non-tumour 
mucosa 32 weeks after AOM injection. Results showed that, in contrast to the pattern during 
early timepoints, obese colon expressed higher amounts of Cdc7 than lean in the late 
timepoint (Figure 14), consistent with increased cellular proliferation signaling from obese rat 
adipocyte populations (see section 1.8). PCNA levels, however, were unexpectedly not 
significantly increased in obese rat colonic mucosa vs. lean (Figure 14). This suggests that 
upregulation of initiation factors in response to pr liferation signaling is not sufficient to 
increase abundance of all fork components. In particular, PCNA expression may be inhibited 




Figure 14. Cdc7 levels are higher in obese normal-appearing colonic mucosa vs. lean 
once tumours have appeared. Whole soluble protein extracts from non-tumour mucosa f 
Zucker obese and lean rats collected 32 weeks following AOM challenge were prepared as 
for previous Zucker rats (see Figure 10-Figure 13).Cdc7 and PCNA protein levels were 
detected by immunoblotting, and resulting bands were quantified by spot densitometry. 
Measurements obtained were normalized to that of total protein (measured by Ponceau S 
staining) for each sample and averaged over the total number of samples in each group. 
Normalized levels are shown graphically as means ±standard deviation (nobese=5; nlean=5). 
Densitometry was performed using Image J software (NIH). Asterisk (*) indicates significant 
difference between obese and lean mucosa (p<0.05). 
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3.3.2 PCNA, but not Cdc7, levels are significantly higher in obese tumours relative to 
adjacent mucosa 
PCNA has been commonly used as a tumour marker for a multitude of tissues from 
animal models as well as humans (reviewed in Semple & Duncker, 2004). Previous studies 
have demonstrated that Cdc7 is upregulated in tumours compared to adjacent colon mucosa, 
as judged by RT-PCR analysis of rat tissues (Hess et al., 1998). More recent studies have 
shown similar results in human cell lines and resected human samples (Bonte et al., 2008). To 
assess whether increased Cdc7 and PCNA levels seen in human tumour tissue would extend 
to an obese rat model, Cdc7 and PCNA expression were compared between tumours and 
adjacent mucosa from Zucker obese rats terminated 32 weeks after AOM injection. 
Quantification for Cdc7 was made difficult by an unusual amount of nonspecific binding of 
unknown origin (Figure 15) between lanes. The resulting background noise persisted on all 
subsequently developed films, and its etiology remained undiagnosed despite extensive 
troubleshooting. Nevertheless, inspection of Figure 14 shows mucosal levels of Cdc7 which 
are approximately equal to or greater than those of obese rat colonic tumours, which supports 
densitometric measurements showing that obese rat coloni  mucosa did not significantly 
differ from obese tumour tissue in Cdc7 levels at this late timepoint.  Combined with results 
which demonstrate that obese mucosal Cdc7 levels ar ignificantly higher than those of their 
lean counterparts at this late timepoint (Figure 14), it is likely that abnormal proliferation 
signaling in obese non-tumour mucosa results in upregulation of mucosal Cdc7 which is not 
seen in non-obese tissues.  
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PCNA, but not Cdc7, appeared more abundant in the single lean tumour than adjacent 
mucosa (see Figure A 3 in the Appendix), supporting PCNA as a more sensitive tumour 
marker than Cdc7. Both Cdc7 and PCNA expression appeared comparable between some 
obese tumour samples and the single lean one (see Figure A 4 in the Appendix), suggesting 
that neither may be a marker of tumour growth aggression.  
Results of comparisons of Cdc7 and PCNA levels betwe n obese and lean rat tissues 
are summarized in Figure 16. Quotient of mean values (obese/lean; denoted OL) was 
determined to show obese rat tissue protein levels relative to lean. OL greater than 1 indicates 
timepoints at which obese animals had higher colonic mucosal levels of Cdc7 or PCNA than 
lean animals. A decreased Cdc7 OL between uninjected animals and those terminated 3h 
post-AOM (Figure 16) combined with early timelines showing a non-significant decrease in 
Cdc7 colonic mucosal levels in both obese and lean rats between colonic mucosa over the 
same period (see Figure A 1 and Figure A 2 in the Appendix) suggests that Cdc7 levels drop 
in both lean and obese rat colonic mucosa but to a lesser extent in lean. The reduction in Cdc7 
levels in lean animals during the first 3h post-AOM suggests that even in a system where the 
DNA damage response is robust, total Cdc7 is reduced following DNA damage. This overall 
reduction could result from combined downregulation of Cdc7 to inhibit late origin firing and 
upregulation of Cdc7 to support checkpoint signaling. Impaired checkpoint signaling in obese 
rats would then cause them to express less total Cdc7 than lean rats. Following this initial 
drop, Cdc7 OL levels climb steadily (Figure 16), as do Cdc7 levels of both obese (Figure A 1) 
and lean (Figure A 2) rat colonic mucosa. Taken together, these results suggest that 
proliferation signaling is steadily increasing throughout carcinogenesis in both phenotypes, 
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Figure 15. Obese colonic mucosa expresses similar levels of Cdc7, but not PCNA, to 
obese colonic tumours. Whole soluble protein extracts from colonic tumours and colonic 
mucosa of Zucker obese rats collected 32 weeks after AOM challenge were prepared as for 
previous Zucker rats (see Figure 10-Figure 14). Cdc7 and PCNA protein levels were 
detected by immunoblotting, and resulting bands were quantified by spot densitometry. 
Measurements obtained were normalized to that of total protein (measured by Ponceau S 
staining) for each sample and averaged over the total number of samples in each group. 
Normalized levels are shown graphically as means ± standard deviation (ntumours=6; 
nmucosa=5). Densitometry was performed using Image J software (NIH). Asterisk (*) 













































































Figure 16. Summary of obese vs. lean rat colonic protein expression during colon 
carcinogenesis: Ratio of obese to lean rat colonic Cdc7 levels correlates with expected 
degree of hyperproliferation, whereas increased ratio of obese to lean rat colonic PCNA 
levels appears to indicate presence of neoplasia. A. Ratio of obese to lean rat colonic 
mucosal Cdc7 levels initially drops, suggesting successful late origin inhibition is coupled 
with impaired checkpoint response in obese animals. Cdc7 levels then increase in obese 
relative to lean rat colonic mucosa with time. B. In contrast to relative levels of Cdc7, obese 
rat colonic mucosal PCNA levels are similar to that of lean rats (approximately 1:1) at least 
during early carcinogenesis. An increase in the ratio of obese to lean PCNA levels in 32-week-
post-AOM mucosa results from high variability in obese rat colonic mucosal PCNA levels at 
that timepoint, which were not significantly different from values for lean rats (see Figure 14).
There was only a single lean tumour, so it was not possible to determine if obese rat colonic 
tumours differed significantly in protein expression from lean rat colonic tumours. Asterisk (*) 
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but to a greater extent in obese animals. PCNA OLs, in contrast, are uniformly close to 1 
during early timepoints, suggesting that PCNA levels are not affected by obese metabolic 
state the same way Cdc7 levels are, possibly due to post-transcriptional inhibition of PCNA. 
At 32 weeks post-AOM, an apparent increase in PCNA OL levels is seen to result from a 
single obese rat colonic mucosal sample (Figure 14), suggesting that PCNA OL levels remain 
constant until a threshold population of dysplastic or neoplastic cells is present. This 
population is expected to be larger in obese animals at this late timepoint because they have 
enhanced tumour risk.  
Tumour tissue is not the same as non-tumour tissue, and hence it is not always obvious 
whether protein factor expression should be increased or decreased in colonic tumours 
depending on their metabolic environment. Both Cdc7 and PCNA OL levels were increased 
compared to early timepoints (Figure 16). However, b cause only a single lean tumour sample 
was available, statistical determination of differenc s in Cdc7 and PCNA levels between 
obese and lean rat colonic tumours was not possible. Inspection of Figure A 4 nevertheless 
shows that the majority of obese tumour samples expressed more Cdc7 and PCNA than the 
single lean tumour sample. Whether obese rat colonic tumours have higher levels of these 
replication factors, consistent with enhanced proliferation signaling in obese tumours, or 
obese and lean rat colonic tumours have expression profiles more closely resembling each 
other than the normal tissue from which they arose, is unclear from these results.
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3.4 Study 3: Late events in colon carcinogenesis in the Sprague Dawley rat 
model 
3.4.1 Cdc7 and PCNA levels are increased in AOM-induced colonic tumours in 
Sprague Dawley rats 
Animal research in colon cancer is not restricted to obese rat models. The utility of a 
protein biomarker as a research tool relies in part on i s extendability to species which are in 
common use. To confirm that Cdc7 and PCNA protein lvels are upregulated in common 
laboratory rat tumour tissue, we compared Cdc7 and PCNA expression in AOM-induced 
tumour tissue to adjacent mucosal tissue from Sprague Dawley rats via western blot. Results 
showed increased Cdc7 and PCNA levels in tumour tissue relative to adjacent mucosa, 
(p<0.05; Figure 17), consistent with previous studies in human cell lines and human tissues 
(Bonte et al., 2008) and compatible with dysregulation of cellular proliferation in  tumour 
tissue. Significantly higher Cdc7 levels in Sprague Dawley tumours than mucosa contrasts 
with results showing no difference between tumour and mucosal Cdc7 levels in Zucker obese 
animals (Study 2), suggesting that the utility of Cdc7 as a biomarker may rely on metabolic 
state. This dependence is not shared by PCNA, suggetin  it may be a more robust tumour 
marker in general. However, Cdc7 expression was increased in all six of the Sprague Dawley 
tumour samples, but only four of the six tumour samples expressed more PCNA, suggesting 
that Cdc7, like many other pre-replication factors, is a more sensitive tumour marker. Overall, 
these results support the utility of both Cdc7 and PCNA as colonic tumour markers in the 
Sprague Dawley rat.  
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Figure 17. Cdc7 and PCNA levels are significantly increased in tumours vs. normal-
appearing colon mucosa in Sprague Dawley rats. Whole soluble protein extracts from 
tumours and remaining mucosa of Sprague Dawley rats 32 weeks post-AOM challenge were 
prepared by homogenization in modified RIPA buffer ollowed by centrifugation. Extracted 
proteins were resolved by SDS-PAGE and immunoblotted with antibodies for Cdc7 and 
PCNA. Densitometric quantitation of resulting bands was normalized to that of total protein 
(measured by Ponceau) for each sample. Resulting values veraged over total number of 
samples are shown graphically as means ± standard deviation (ntumours=6; nmucosa=6). 
Densitometry was performed using Image J software (NIH). Asterisk (*) indicates a 






































































 As previously mentioned, mucosa adjacent to rat colonic tumours is 
hyperproliferative, typically with ACF numbers of over 200 and average crypt multiplicity of 
more than 4 (Shivapurkar et al., 1996). Interestingly, PCNA was barely detectable in mucosa 
relative to tumours, while Cdc7 showed a strong signal in mucosa, with tumour levels 
stronger still (Figure 17). These results suggest that Cdc7 may additionally be a more 
sensitive marker of hyperproliferation than PCNA.  
Since Mcm2 is a target of Cdc7 kinase activity and has previously been shown to be 
upregulated in dysplastic colonic crypts (Scott et al., 2003), we attempted to evaluate the 
samples for MCM2 levels using antibodies which were purported to detect rat antigen; 
however, the antibody, which clearly binds the HeLa (human) positive control antigen, does 
not appear to bind at all to the Sprague Dawley rat samples (see Figure A 5 in the Appendix). 
To assess whether the lack of affinity of the Mcm2 antibody for Sprague Dawley antigen is 
unique to that strain, we used it to assess mucosal samples from Zucker lean rats, another 
strain of Rattus norvegicus (see Figure A 6 in Appendix). Results were similar to those for 




Chapter 4.  Discussion 
 To summarize the results of this investigation, western blot analysis was used to assess 
the protein expression of Cdc7 and PCNA during colon carcinogenesis in AOM-induced 
obese and lean rat models. It was shown that during the DNA damage response, Cdc7 levels 
were elevated in lean animals relative to obese anim ls well in advance of a similar pattern for 
PCNA levels (see Figure 11 and Figure 13), consistent with an early role for Cdc7 in the 
checkpoint response and a later role for PCNA in repair. Additionally, we showed that Cdc7 
and PCNA levels are elevated in colonic tumours relative to adjacent mucosa in the non-obese 
Sprague Dawley rat model, but Cdc7 levels do not differ between obese tumours and mucosa.  
We propose that Cdc7 is upregulated in lean animals as part of the ATR-Chk1 
checkpoint response immediately upon fork stalling due to the presence of bulky alkyl DNA 
adducts induced by AOM. The increase in Cdc7 abundance is delayed or impaired in obese 
animals, due to cytokine- and fatty acid-mediated impaired DNA damage response (Mena et 
al., 2009; Zeng et al., 2008). Obese animals are consequently at increased risk of sustaining 
irreversible DNA damage following fork collapse and therefore accumulate more transformed 
cells than lean animals. Combined with increased baseline cellular proliferation rates in 
untransformed obese mucosal tissues due to obesity-associated hyperinsulinemia (Mena et al., 
2009), this heightened risk of DNA damage could contribute to the greatly augmented tumour 
incidence seen in obese rats. In colonic tumour tissue, PCNA levels are also increased relative 
to normal-appearing colonic mucosa in both Sprague-Dawley and obese Zucker rats, 
suggesting that excessive upregulation of fork complex factors is an event tolerated only by 
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neoplastic cells. PCNA upregulation may be accomplished in tumour cells by inhibition of 
normally-occurring post-transcriptional repression (Tommasi & Pfeifer, 1999). 
It is possible that the resistance of tumours to damage caused by a highly increased 
replication rate is balanced by increases in expression of DNA damage response factors, 
including Cdc7 and PCNA. The checkpoint factors ATM, Chk2 and p53 are all upregulated in 
breast cancer (Gochhait et al., 2009), although it is not known whether this upregulation 
extends to colonic tumours. Normal cells require less Cdc7 than tumour cells for viability, as 
Cdc7 inhibitors selectively kill tumour cells (Menichincheri et al., 2009; Montagnoli et al., 
2008). Tumour cells may therefore be more heavily reliant on DNA damage response factors 
such as Cdc7 and PCNA during early events. Thus, the involvement of both Cdc7 and PCNA 
in DNA replication and DNA damage response appears to enhance their utility as tumour 
markers. 
4.1 DNA damage response appears more robust in lean than obese 
 Obese Zucker rats have previously been shown to develop more and larger ACF than 
their lean counterparts in response to carcinogen administration, despite having the same 
levels of DNA damage and BrdU-labeled cells per crypt (Koch et al., 2008). In the current 
study, it was found that lean Zucker rats express more Cdc7 protein than obese Zucker rats 
soon after AOM injection, at a time when the DNA damage response cascade is first being 
initiated. The reported role of Cdc7 in claspin phosphorylation during the ATR/Chk1 
checkpoint response (Kim et al., 2008) suggests tha upregulation of Cdc7 could play a part in 
modulating the efficacy of Chk1 activation. This leads to the possibility that the increased 
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Cdc7 levels in lean relative to obese colonic mucosa f llowing AOM injection results from 
the lean rats having mounted a more robust checkpoint response than the obese rats, 
consistent with an increased rate of ACF and tumours in obese animals. 
4.2 Temporal order of Cdc7 and PCNA upregulation is consistent with 
respective roles in DNA damage signaling and fork restart 
 Previous work has suggested that the Cdc7-mediated ATR checkpoint lies upstream of 
DNA damage repair processes in which PCNA is involved (Kim et al., 2008; Kastan & 
Bartek, 2004; Moldovan et al., 2007). Following theATR checkpoint, ubiquitin-modified 
PCNA is involved in some DNA damage repair pathways (reviewed in Moldovan et al., 
2007). It is unclear whether modified PCNA moieties can be deubiquitylated or must be 
replaced with newly expressed PCNA following successful repair (Moldovan et al., 2007) 
causing a concomitant increase in PCNA levels. Monoubiquitylation of PCNA, induced by 
the presence of some DNA lesions, leads to recruitmen  of alternative polymerases whose 
conformation accommodates the lesion (Lee & Myung, 2008). Polyubiquitylation of PCNA is 
thought to be associated with error-free template switching, though the mechanism of this 
repair pathway is poorly understood (Lee & Myung, 2008; Moldovan et al., 2007). In the 
event of template switching, one proposed mechanism is that polyubiquitylated PCNA is 
detached from polymerase δ or ε and marks the site of the lesion; the replicative polymerase 
then traverses the lesion without the original tether, and a new PCNA molecule must replace 
the original one to restore polymerase processivity and replisome cohesion (Moldovan et al., 
2007). By comparing the DNA damage response in lean rats to the impaired pathway seen in 
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obese rats, this study showed that Cdc7 upregulation (Figure 11) precedes PCNA upregulation 
(Figure 13), consistent with these models.  
Cdc7 activity is required to maintain viability during S-phase checkpoint in multiple 
eukaryotic species (Kim et al., 2008; Ogi et al., 2008; Tenca et al., 2007; Tsuji et al., 2008). 
The cellular response to fork stalling involves Cdc7-mediated claspin mediation of Chk1 
activation (Kim et al., 2008). Even within the same organism, some authors argue that the 
resulting checkpoint signal inactivates Cdc7 (Costanzo et al., 2003; Heffernan et al., 2007). It 
is not clear from the present data whether these diff rences result from a relative increase in 
protein levels in lean animals due to a more robust checkpoint response or a relative decrease 
in protein levels in obese animals due to Cdc7 downregulation supporting late origin 
inhibition. However, time course data showed a trend toward an initial drop in Cdc7 levels 
between obese uninjected control mucosa and that of AOM-challenged obese animals 3 hours 
after injection (Figure A 1) which was not seen in lean animals (Figure A 2). Both obese 
phenotypes subsequently showed a slow rising trend during the following timepoints, 
suggesting that the difference in Cdc7 levels 3h post-AOM was due to a relative decrease in 
obese protein levels. While it would be simple to conclude that obese checkpoint more 
efficiently downregulates Cdc7 following DNA damage, that would be inconsistent with 
increased risk for tumour development in obese animls. It is more likely that multiple 
pathways cause Cdc7 to be effectively downregulated to prevent late origin firing in both 
phenotypes but more effectively upregulated to support checkpoint signaling in lean rats. 
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4.3 Cdc7 protein upregulation in tumours does not extend to the obese rat 
model 
This study demonstrated that the differences in Cdc7 expression between tumour and 
mucosa seen in human tissues and cell lines (Bonte et al., 2008) do not extend to the obese rat 
model. Hyperinsulinemia characteristic of obese anim ls (Argiles, 1989) is known to increase 
cell proliferation signaling (Mena et al., 2009). Cdc7 levels may be upregulated in response to 
these aberrant signals.  
Hyperinsulinemia does not appear to cause an increase in PCNA levels to the extent 
that it increases Cdc7 levels in obese animals relativ  to lean animals in non-tumour colonic 
mucosa at early timepoints (Figure 16). Early timepoints comprise a period during which 
dysplastic and neoplastic cells are unlikely to be present, whereas mucosa adjacent to tumour 
tissue contains dysplastic cells and may contain microscopic neoplasms detectable only on 
histological examination. In this study, tumour samples originated from visible tumours, and 
mucosal samples originated from the remaining mucosa, which could easily have contained 
undetected neoplastic cells. Additionally, normal-appearing mucosa from obese rats at late 
timepoints likely contains more dysplastic and neoplastic cells than that from lean rats at the 
same timepoint, since obese animals are at higher risk for cellular transformation (Weber et 
al., 2000). Therefore, the lack of a pronounced increase in PCNA levels comparable to that of 
Cdc7 levels during early timepoints in obese rat colonic mucosa relative to lean rat colonic 
mucosa may reflect a low rate of dysplasia and neoplasia in these tissues. Significantly higher 
PCNA levels in obese rat colonic tumours than non-tumour colonic mucosa (Figure 15) 
combined with the absence of significant differences b tween PCNA levels in obese and lean 
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rat non-tumour colonic mucosa at the same timepoint (F gure 14) suggests that an increase in 
mucosal PCNA concomitant to that of Cdc7 is not necessarily a consequence of obese cell 
cycle dysregulation. The lack of correlation between Cdc7 levels and PCNA levels could be 
due to dissimilar transcriptional promotion, post-transcriptional expression modulation, post-
translational degradation, or a combination of these.  The PCNA gene encodes an antisense 
RNA transcribed from a promoter in intron 1, which s thought to mediate post-transcriptional 
PCNA expression inhibition (Tommasi & Pfeifer, 1999). Transcription of this antisense RNA 
is activated in part by E2F, which upregulates the Cdc7 activator, ASK (Yamada et al., 2002) 
and has putative binding sites in the murine Cdc7 promoter (Kim et al., 1998), suggesting that 
PCNA upregulation follows Cdc7 activity during the normal cell cycle. Gene-specific, PCNA 
expression inhibition may therefore be accomplished post-transcriptionally through binding of 
transcription factors which upregulate ASK and may upregulate Cdc7 itself. 
Obese mucosa at late timepoints is likely to contain more precancerous tissue than 
lean, since obese animals are at much higher risk of developing tumours than lean animals. 
These tissues contain dysplastic cells which may already require an enhanced DNA damage 
response to maintain viability in the face of dysregulated proliferation, causing Cdc7 levels to 
necessarily increase to feed the chain of activation. This suggests that obese tumours are more 
checkpoint competent than obese untransformed tissue, and would therefore likely more 
closely resemble lean tumours in their expression of checkpoint proteins. While our data was 
insufficient to statistically test this hypothesis, abundance of both Cdc7 and PCNA in the 
single lean colonic tumour sample was certainly within he range of that of obese colonic 
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tumours, supporting the possibility that DNA damage response robustness may be similar 
between lean and obese tumours. 
In the lean rat model, we saw significantly fewer tumours than in the obese rats  
(1 tumour/10 lean rats vs. 6 tumours/5 obese rats). Previous studies employing a single dose 
of the AOM precursor 1,2-dimethylhydrazine (DMH) showed that the non-obese Sprague 
Dawley rat fails to develop macroscopic lesions as late as 41 weeks post-challenge, even at a 
dose of 125 mg/kg (McLellan et al., 1991b), well above currently employed dosages of 20-30 
mg/kg for 1-3 doses (Yusup et al., 2009; Zhi et al., 2007).  This is consistent with reduced 
carcinogen sensitivity in non-obese rats leading to lowered tumour risk.  
When challenged with two doses of AOM at 10 mg/kg, obese Zucker rats develop 
significantly more intermediate (4-6 crypts) and adv nced (>7 crypts) ACF, but not 
significantly more primal ACF (1-3 crypts) or total ACF than lean Zucker rats nine weeks 
after the second injection (Raju & Bird, 2003), suggesting that obese aberrant crypts are 
simply more prone to clonal expansion. Also, non-obese Sprague Dawley rats develop more 
total, small and large ACF following two weekly AOM doses at 15 mg/kg body weight than 
obese Zuckers develop following two weekly doses at 10 mg/kg body weight (Eskin et al., 
2007), suggesting that the dose reduction for Zucker is sufficient to slow the early phases of 
preneoplasia. Our results, however, demonstrate tha even with two larger doses of AOM, 
non-obese Sprague Dawley colonic mucosa does not cotain the increased levels of Cdc7 




4.4 Cdc7 and PCNA protein upregulation in human tumours extends to a 
Sprague Dawley rat model 
 Previous studies examining Cdc7 protein as a marker for colon cancer focused on 
human samples and cell lines (Bonte et al., 2008). This study demonstrated that Cdc7 protein 
levels were upregulated in Sprague Dawley rat tumours compared with adjacent mucosa 
(Figure 17). It is interesting that Cdc7 showed a much stronger signal in the mucosa than 
PCNA, since mucosa adjacent to tumours is hyperprolife ative, containing hundreds of ACF 
(Shivapurkar et al., 1996). This could be due to the kinetics of upregulation of Cdc7 vs. 
PCNA in the DNA damage response, DNA replication, or b th. Perhaps, for instance, much 
more Cdc7 is expressed in response to DNA damage than PCNA.  This is particularly likely 
since only a small proportion of lesions which induce the ATR-Chk1 pathway will result in 
fork collapse and hence PCNA modifications which direct DNA repair mechanisms 
(Ampatzidou et al., 2006). The observed differences could also result from post-




4.5 Conclusions and future directions 
The major findings of this work are: 
1. The temporal order of Cdc7 and PCNA upregulation immediately following DNA 
damage induction is consistent with a model in which Cdc7 mediates the early 
checkpoint response to DNA alkylation-stalled replication forks prior to PCNA 
upregulation following translesion synthesis; 
2. Both Cdc7 and PCNA appear to be elevated in colonic tumours; however, obese 
metabolic state appears to obscure the difference in Cdc7 level between tumours 
and colonic mucosa; 
3. PCNA remains an effective tumour marker regardless of metabolic state. 
A model of the DNA damage response which is supported by the expression patterns 
seen in this work and which is consistent with previous literature (Branzei & Foiani, 2005; 
Moldovan et al., 2007) is shown in Figure 18. In lean animals immediately following 
carcinogen challenge, fork stalling caused by the presence of DNA alkyl adducts has initiated 
the ATR checkpoint cascade, requiring the upregulation of Cdc7 to mediate claspin 
phosphorylation necessary for Chk1 activation (Kim et al., 2008).  By 24h post-challenge, 
PCNA is upregulated to replace ubiquitin-modified moieties still encircling the lesion site 




Figure 18. Role of Cdc7 and PCNA in DNA damage response and obese cancer risk. During 
early timepoints in lean animals, Cdc7 is upregulated to support ATR-Chk1 pathway initiation by 
fork stalling. The ATR-Chk1 pathway acts to promote fork stabilization. PCNA is upregulated 
only in the relatively rare event that fork stabilization is unsuccessful, to replace modified 
moieties which no longer support DNA polymerase δ/ε processivity. Obese animals suffer from 
an impaired DNA damage response, which may extend to repair processes. This increases their 
risk of cellular transformation by reducing the incidence of successful DNA damage repair. 
Proliferation of obese cells is enhanced by hyperinsul emia, causing an increased tumour 
growth rate. Yellow boxes indicate intact DNA damage response pathways and factors which are 
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suggesting that pathways leading to successful repair are inhibited. Therefore, there is a 
pathway shift in obese animals towards unsuccessful DNA damage response and hence 
towards cancer. 
Late in carcinogenesis, colonic mucosa of both obese and lean rats is highly 
hyperproliferative and likely contains some dysplastic cells (Bird, 1995). At the same time, 
obese mucosal tissue displays increased Cdc7 expression due to increased cellular 
proliferation signals in its hyperinsulinemic environment (Mena et al., 2009). Increased Cdc7 
expression in obese mucosa therefore eliminates the difference between tumour and mucosal 
Cdc7 expression seen in the non-obese Sprague Dawley rats. 
Our findings have clearly demonstrated that use of a single tumour marker is 
inadvisable. We have shown that Cdc7 is a more sensitive marker than PCNA but is reliable 
as a tumour marker only in lean animals, suggesting the need for supplementary markers. 
Future studies could broadly target the importance of cell cycle factors and factors involved in 
DNA damage and repair in lean and obese metabolic environments during different stages of 
colon carcinogenesis using techniques such as gene and protein microarrays. Incorporation of 
phospho-specific antibodies in the protein microarrays could aid in assessing the activation 
state of checkpoint signaling factors such as ATR, Chk1 and claspin. Further investigation of 
these aspects will lead to a better understanding of the DNA damage response and the 








Figure A 1. No significant differences in Cdc7 or PCNA level were seen between 
timepoints during early events in obese Zucker colonic mucosa. Obese samples 
used for obese vs. lean comparisons (see Figure 10-Figure 13) were re-blotted to 
examine differences between timepoints. Densitometry was performed using ImageJ, 
as before. Group means ± standard deviation are shown graphically. Significant 
differences as determined by Student’s t-test of neither Cdc7 nor PCNA levels between 
mucosa from obese uninjected (n=3), obese 3h post-AOM (n=3), obese 9h post=AOM 

























































































Figure A 2. No significant differences in Cdc7 or PCNA level were seen 
between timepoints during early events in lean Zucker colonic mucosa. 
Lean samples used for obese vs. lean comparisons (see Figure 10-Figure 13) 
were evaluated by western blot to examine differences between timepoints. 
Densitometry was performed using ImageJ, as before. Group means ± 
standard deviation are shown graphically. Neither Cdc7 nor PCNA levels 
differed significantly between colonic mucosa from lean rats which were 
uninjected (n=3), 3h post-AOM (n=3), 9h post=AOM (n=3), and 24h post-


































































































Figure A 3. The single lean tumour appeared 
to express more PCNA but not Cdc7 than 
lean mucosa. Whole soluble protein extracts 
from the single colonic tumour (n=1) and 
colonic mucosa (n=5) of challenged Zucker lean 
rats collected 32 weeks after AOM challenge 
were prepared as for previous Zucker tissues 
(see Figure 10-Figure 15). Cdc7 and PCNA 
















Figure A 4. The single lean tumour falls within the distribution of obese 
Cdc7 and PCNA expression. Obese (n=6) and lean (n=1) colonic tumour 
samples used for comparison with colonic mucosa were re-blotted for 
comparison with each other. While the uniqueness of the lean tumour sample 
made statistical comparisons impossible, visual inspection of the bands shows 
that the lean tumour sample expresses amounts of both Cdc7 and PCNA which 
fall in the range of those of the obese tumour samples. 
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Figure A 5. MCM2 antibody did not have sufficient affinity for Sprague 
Dawley protein. The Sprague Dawley colonic tumour (n=6) and colonic 
mucosa (n=6) samples shown in Figure 17 were assessed for MCM2 levels 
using a commercial antibody. The blot was exposed until the signal elicited by 
the HeLa positive control was saturated. MCM2 signal was undetectable in 













Figure A 6. MCM2 antibody had insufficient affinity for Zucker antigen. 
The blot shown in Figure A 2 was also probed for MC2 using the same 
commercial antibody with which the Sprague Dawley samples were probed 
(see Figure A 5). For this probe, the blot was exposed only until the HeLa 
showed a strong, visible, non-saturated signal, at which point none of the lean 
Zucker samples (uninjected, n=3; 3h post-AOM, n=3; 9h post-AOM, n=3; 
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